INSL5 is a novel marker for human enteroendocrine cells of the large intestine and neuroendocrine tumours

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 149-154

  Thanasupawat, Thatchawan ^a   Hammje, Katrin ^b   Adham, Ibrahim ^c   Ghia, Jean Eric ^d,e   Bigio, Marc R Del ^a,f   Krcek, Jerry ^a,g   Hoang Vu, Cuong ^b   Klonisch, Thomas ^a,g,h   Hombach Klonisch, Sabine ^a,i  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Departments of Human Anatomy and Cell Science   (Canada)

^e Departments of Immunology   (Canada)

^f Departments of Pathology   (Canada)

^g Departments of Surgery   (Canada)

^h Departments of Medical Microbiology and Infectious Diseases   (Canada)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Carcinoid; Enteroendocrine cells; INSL5; Large intestine; Neuroendocrine tumours

Indexed keywords

INSL5 PROTEIN; RXFP4 PROTEIN; SYNAPTOPHYSIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOID; COLITIS; COLON MUCOSA; COLONOCYTE; CONTROLLED STUDY; DISEASE MARKER; ENTEROENDOCRINE CELL; HUMAN; HUMAN TISSUE; INTESTINE CELL; LARGE INTESTINE; MALE; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

ANIMALS; AUTOCRINE COMMUNICATION; CARCINOID TUMOR; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENTEROENDOCRINE CELLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; INSULIN; INTESTINE, LARGE; MALE; MICE; MICE, KNOCKOUT; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PARACRINE COMMUNICATION; PROGNOSIS; PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84872858647     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2119     Document Type: Article

References (51)

1. Wilkinson TN, Speed TP, Tregear GW and Bathgate RA: Evolution of the relaxin-like peptide family. BMC Evol Biol 5: 14, 2005.
2. Conklin D, Lofton-Day CE, Haldeman BA, et al: Identification of INSL5, a new member of the insulin superfamily. Genomics 60: 50-56, 1999.
3. Liu C, Kuei C, Sutton S, et al: INSL5 is a high affinity specific agonist for GPCR142 (GPR100). J Biol Chem 280: 292-300, 2005.
4. Liu C and Lovenberg TW: Relaxin-3, INSL5, and their receptors. Results Probl Cell Differ 46: 213-237, 2008.
5. Liu C, Chen J, Kuei C, et al: Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7. Mol Pharmacol 67: 231-240, 2005.
6. Chen J, Kuei C, Sutton SW, et al: Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species. J Pharmacol Exp Ther 312: 83-95, 2005.
7. Liu C, Eriste E, Sutton S, et al: Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. J Biol Chem 278: 50754-50764, 2003.
8. Field BC, Chaudhri OB and Bloom SR: Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol 6: 444-453, 2010.
9. Khan WI and Ghia JE: Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol 161: 19-27, 2010.
10. Moran GW, Leslie FC, Levison SE, Worthington J and McLaughlin JT: Enteroendocrine cells: neglected players in gastrointestinal disorders? Therap Adv Gastroenterol 1: 51-60, 2008.
11. Rindi G, Leiter AB, Kopin AS, Bordi C and Solcia E: The 'normal' endocrine cell of the gut: changing concepts and new evidences. Ann NY Acad Sci 1014: 1-12, 2004.
12. Andrew A, Kramer B and Rawdon BB: The origin of gut and pancreatic neuroendocrine (APUD) cells - the last word? J Pathol 186: 117-118, 1998.
13. Gordon JI: Understanding gastrointestinal epithelial cell biology: lessons from mice with help from worms and flies. Gastroenterology 105: 315-324, 1993.
14. Schonhoff SE, Giel-Moloney M and Leiter AB: Minireview: Development and differentiation of gut endocrine cells. Endocrinology 145: 2639-2644, 2004.
15. May CL and Kaestner KH: Gut endocrine cell development. Mol Cell Endocrinol 323: 70-75, 2010.
16. Wiedenmann B, Franke WW, Kuhn C, Moll R and Gould VE: Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA 83: 3500-3504, 1986.
17. Gunawardene AR, Corfe BM and Staton CA: Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol 92: 219-231, 2011.
18. West NE, Wise PE, Herline AJ, Muldoon RL, Chopp WV and Schwartz DA: Carcinoid tumors are 15 times more common in patients with Crohn's disease. Inflamm Bowel Dis 13: 1129-1134, 2007.
19. Kang H, O'Connell JB, Leonardi MJ, Maggard MA, McGory ML and Ko CY: Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis 22: 183-189, 2007.
20. Soga J: Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res 22: 517-530, 2003.
21. Modlin IM and Sandor A: An analysis of 8305 cases of carcinoid tumors. Cancer 79: 813-829, 1997.
22. Modlin IM, Lye KD and Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97: 934-959, 2003.
23. Soga J: Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer 103: 1587-1595, 2005.
24. Grabowski P, Schonfelder J, Ahnert-Hilger G, et al: Heterogeneous expression of neuroendocrine marker proteins in human undifferentiated carcinoma of the colon and rectum. Ann NY Acad Sci 1014: 270-274, 2004.
25. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y and Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702, 1990.
26. Sturiale S, Barbara G, Qiu B, et al: Neutral endopeptidase (EC 3. 4. 24. 11) terminates colitis by degrading substance P. Proc Natl Acad Sci USA 96: 11653-11658, 1999.
27. Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI and Collins SM: Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology 136: 2280-2288, 2009.
28. Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249, 1993.
29. Burnick-Turek O, Mohamed BA, Shirneshan K, et al: INSL5-deficient mice display an alteration in glucose homeostasis and impaired fertility. Endocrinology 153: 4655-4665, 2012.
30. Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G and Blanchard JF: Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 95: 677-683, 2000.
31. El-Salhy M, Danielsson A, Stenling R and Grimelius L: Colonic endocrine cells in inflammatory bowel disease. J Intern Med 242: 413-419, 1997.
32. Wang H, Steeds J, Motomura Y, et al: CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut 56: 949-957, 2007.
33. Ahonen A, Kyosola K and Penttila O: Enterochromaffin cells in macrophages in ulcerative colitis and irritable colon. Ann Clin Res 8: 1-7, 1976.
34. Klonisch T, Bialek J, Radestock Y, Hoang-Vu C and Hombach-Klonisch S: Relaxin-like ligand-receptor systems are autocrine/paracrine effectors in tumor cells and modulate cancer progression and tissue invasiveness. Adv Exp Med Biol 612: 104-118, 2007.
35. Jaspers S, Lok S, Lofton-Day CE, et al (eds): The Genomics of Insulin 5. Kluwer Academic Publishers, Dordrecht, 2001.
36. Jahn R, Schiebler W, Ouimet C and Greengard P: A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc Natl Acad Sci USA 82: 4137-4141, 1985.
37. Gould VE, Lee I, Wiedenmann B, Moll R, Chejfec G and Franke WW: Synaptophysin: a novel marker for neurons, certain neuroendocrine cells, and their neoplasms. Hum Pathol 17: 979-983, 1986.
38. Buffa R, Rindi G, Sessa F, et al: Synaptophysin immunoreactivity and small clear vesicles in neuroendocrine cells and related tumours. Mol Cell Probes 1: 367-381, 1987.
39. Bjerknes M and Cheng H: Neurogenin 3 and the enteroendocrine cell lineage in the adult mouse small intestinal epithelium. Dev Biol 300: 722-735, 2006.
40. Cortina G, Smart CN, Farmer DG, et al: Enteroendocrine cell dysgenesis and malabsorption, a histopathologic and immunohistochemical characterization. Hum Pathol 38: 570-580, 2007.
41. Skipper M and Lewis J: Getting to the guts of enteroendocrine differentiation. Nat Genet 24: 3-4, 2000.
42. Bishop AE, Pietroletti R, Taat CW, Brummelkamp WH and Polak JM: Increased populations of endocrine cells in Crohn's ileitis. Virchows Arch A Pathol Anat Histopathol 410: 391-396, 1987.
43. Linden DR, Chen JX, Gershon MD, Sharkey KA and Mawe GM: Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 285: G207-G216, 2003.
44. Oshima S, Fujimura M and Fukimiya M: Changes in number of serotonin-containing cells and serotonin levels in the intestinal mucosa of rats with colitis induced by dextran sodium sulfate. Histochem Cell Biol 112: 257-263, 1999.
45. O'Hara JR, Ho W, Linden DR, Mawe GM and Sharkey KA: Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitis. Am J Physiol Gastrointest Liver Physiol 287: G998-G1007, 2004.
46. Ghia JE, Li N, Wang H, et al: Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 137: 1649-1660, 2009.
47. Feng S, Agoulnik IU, Truong A, et al: Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer 17: 1021-1033, 2010.
48. Vinall RL, Mahaffey CM, Davis RR, et al: Dual blockade of PKA and NF-?B inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm Cancer 2: 224-238, 2011.
49. Hombach-Klonisch S, Bialek J, Radestock Y, et al: INSL3 has tumor-promoting activity in thyroid cancer. Int J Cancer 127: 521-531, 2010.
50. Akhter Hossain M, Bathgate RA, Kong CK, et al: Synthesis, conformation, and activity of human insulin-like peptide 5 (INSL5). Chembiochem 9: 1816-1822, 2008.
51. Belgi A, Hossain MA, Shabanpoor F, et al: Structure and function relationship of murine insulin-like peptide 5 (INSL5): free C-terminus is essential for RXFP4 receptor binding and activation. Biochemistry 50: 8352-8361, 2011.